drugset / Trial / NCT03950544

The Combined Antibiotic Therapy for Carbapenem Resistant Klebsiella Pneumoniae

NCT03950544

Phase 0 Unknown 80 enrolled Shanghai 10th People's Hospital
SequentialOpen-labelTreatment

Summary

The infection of carbapenem resistant klebsiella pneumoniae (CRKP) is increasingly serious.Based on the early experimental basis and relevant research background,this study intends to separate and purify the CRKP from the bronchoalveolar lavage fluid (BALF) of the clinical patients.Designed by checkerboard assay and time-kill assay(TKA),this study can explore the best combination therapy based on carbapenems.

Timeline

Start
2019-01-01
Primary completion
2020-08-31
Completion
2020-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Fosfomycin Small molecule
Subject Meropenem Small molecule
Subject Polymyxin B Peptide
Subject Tigecycline Small molecule